Published in Women's Health Weekly, September 29th, 2005
In a recent report, researchers in the United States conducted a study "to present the basis of the decision of the Food and Drug Administration (FDA) to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen. The FDA reviewed the data from the MA17 trial, a single, multinational, randomized, double-blind, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.